Long-term remission of primary cutaneous neutrophil-rich CD30+ anaplastic large cell lymphoma treated with topical imiquimod. A case report

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 5, 2016, Pages 899-901

  Calista, D ^a   Riccioni, L ^a   Bagli, L ^b   Valenzano, F ^c  

^a BUFALINI HOSPITAL   (Italy)

^b Laboratorio Unico di Area Vasta Romagna   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; GRANZYME B; IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; BEDTIME DOSAGE; BURNING SENSATION; CANCER DIAGNOSIS; CANCER REGRESSION; CASE REPORT; CELL INFILTRATION; DISEASE DURATION; EROSION; ERYTHEMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; LARGE CELL LYMPHOMA; LETTER; MALE; NEUTROPHIL; NOSE; PHYSICAL EXAMINATION; PRIMARY CUTANEOUS NEUTROPHIL RICH CD30 ANAPLASTIC LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BLEEDING; SKIN DEFECT; SKIN NODULE; SKIN SCAR; AGED; FEMALE; IMMUNOLOGY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MIDDLE AGED; REMISSION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AMINOQUINOLINES; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 84971671379     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13070     Document Type: Letter

References (9)

1. Delsol G, Falini B, Muller-Hermelink HK, et al,. Anaplastic large cell lymphoma (ALCL) ALK-positive. In, Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri SA, Stein H, Thiele J, Vardiman, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World health Organization IARC press, Lyon, 2008: 312-316.
2. Kempf W, Willemze R, Jaffe ES, Burg G, Kadin ME,. CD30+ T-cell lymphoproliferative disorders. In, LeBoit PE, Burg G, Weedon D, Sarasin A, eds. Pathology & Genetics-Skin Tumours. World health Organization IARC press, Lyon, 2006: 179-181.
3. Mann KP, Hall B, Kamino H, Borowitz MJ, Ratech H,. Neutrophil-rich, Ki-1-positive anaplastic large cell malignant lymphoma. Am J Surg Pathol 1995; 19: 407-416.
4. Burg G, Kempf W, Kazakov DV, et al,. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol 2003; 148: 580-586.
5. Garland SM,. Imiquimod. Curr Opin Infect Dis 2003; 16: 85-89.
6. David CV, Nguyen H, Goldenberg G,. Imiquimod: a review of off-label clinical applications. J Drugs Dermatol 2011; 10: 1300-1306.
7. Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R,. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004; 150: 1198-1201.
8. Coors EA, Schuler G, Von Den Driesch P,. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol 2006; 16: 391-393.
9. Ehst BD, Dréno B, Vonderheid EC,. Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream. Eur J Dermatol 2008; 18: 467-468.